Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) - Total Liabilities
Based on the latest financial reports, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has total liabilities worth CN¥161.98 Million CNY (≈ $23.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Zhejiang Wolwo Bio-Pharmaceutical Co Ltd total assets.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IReader Technology Co Ltd
SHG:603533
|
China | CN¥572.63 Million |
|
Siloam International Hospitals
JK:SILO
|
Indonesia | Rp5.29 Trillion |
|
Ipsos SA
PA:IPS
|
France | €1.46 Billion |
|
JHSF Participações S.A.
SA:JHSF3
|
Brazil | R$10.70 Billion |
|
Nomad Foods Ltd
NYSE:NOMD
|
USA | $3.84 Billion |
|
Pharma Mar S.A.
MC:PHM
|
Spain | €143.25 Million |
|
Neinor Homes SLU
MC:HOME
|
Spain | €2.42 Billion |
|
Bonesupport Holding AB
ST:BONEX
|
Sweden | Skr169.24 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Zhejiang Wolwo Bio-Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below shows the annual total liabilities of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥250.30 Million ≈ $36.63 Million |
-3.16% |
| 2023-12-31 | CN¥258.46 Million ≈ $37.82 Million |
+51.36% |
| 2022-12-31 | CN¥170.76 Million ≈ $24.99 Million |
+26.16% |
| 2021-12-31 | CN¥135.36 Million ≈ $19.81 Million |
+76.69% |
| 2020-12-31 | CN¥76.61 Million ≈ $11.21 Million |
+0.47% |
| 2019-12-31 | CN¥76.25 Million ≈ $11.16 Million |
+22.06% |
| 2018-12-31 | CN¥62.47 Million ≈ $9.14 Million |
+32.77% |
| 2017-12-31 | CN¥47.05 Million ≈ $6.89 Million |
+13.88% |
| 2016-12-31 | CN¥41.32 Million ≈ $6.05 Million |
+44.60% |
| 2015-12-31 | CN¥28.57 Million ≈ $4.18 Million |
+60.95% |
| 2014-12-31 | CN¥17.75 Million ≈ $2.60 Million |
+47.51% |
| 2013-12-31 | CN¥12.04 Million ≈ $1.76 Million |
+23.65% |
| 2012-12-31 | CN¥9.73 Million ≈ $1.42 Million |
-50.29% |
| 2011-12-31 | CN¥19.58 Million ≈ $2.87 Million |
-2.49% |
| 2010-12-31 | CN¥20.08 Million ≈ $2.94 Million |
+111.50% |
| 2009-12-31 | CN¥9.49 Million ≈ $1.39 Million |
-- |
About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more